Isoniazid, often abbreviated as INH, is a potent antibiotic that has been a fundamental component in the treatment and prevention of tuberculosis (TB) for over half a century. Since its introduction in the 1950s, Isoniazid has saved countless lives and remains a foundation of TB therapy worldwide. It is primarily used to treat active tuberculosis infections, typically in combination with other antituberculosis drugs such as rifampin, ethambutol, and pyrazinamide, to prevent the development of drug resistance. Also, Isoniazid is used as a prophylactic agent in individuals with latent TB infection to prevent the progression to active disease. At Happy Family Pharmacy, we offer Isoniazid for those who need this essential medication, ensuring accessibility and affordability for patients undergoing TB treatment. The medication is available in tablet form, typically in 100 mg and 300 mg strengths, and an oral solution for patients who have difficulty swallowing tablets. This comprehensive guide will provide you with detailed information about Isoniazid, covering its mechanism of action, therapeutic uses, potential side effects, precautions, drug interactions, and proper usage guidelines. Whether you are a patient about to start treatment, a caregiver, or simply seeking knowledge, this article aims to equip you with the information necessary to understand and safely use Isoniazid.
The mechanism by which Isoniazid works is unique and specific to Mycobacterium tuberculosis, the bacterium that causes TB. Isoniazid is a prodrug, meaning it must be activated within the bacterial cell by an enzyme called catalase-peroxidase (KatG) before it becomes active. Once activated, Isoniazid inhibits the synthesis of mycolic acids, which are essential components of the mycobacterial cell wall. Mycolic acids are long-chain fatty acids that form a waxy, impermeable barrier around the mycobacterium, protecting it from the host’s immune system and from many antibiotics. By disrupting the production of mycolic acids, Isoniazid compromises the integrity of the bacterial cell wall, leading to cell death. This specific mechanism explains why Isoniazid is effective against mycobacteria but has little effect on other types of bacteria. The drug is bactericidal, meaning it kills actively growing mycobacteria, which is why it is so effective in treating active TB disease. However, it is less effective against dormant or slow-growing bacteria, which is why it must be used in combination with other drugs for a prolonged period to fully eradicate the infection. Understanding this mechanism is important for appreciating why adherence to the full treatment regimen is so important. Incomplete treatment can not only fail to cure the disease and lead to the development of drug-resistant strains of TB, which are much more difficult and costly to treat. The development of resistance to Isoniazid is a significant global health concern, and efforts to combat it include the use of directly observed therapy (DOT) and fixed-dose combination tablets.
What is isoniazid and how does it work?
Isoniazid, chemically known as isonicotinic acid hydrazide, is a synthetic antibacterial agent discovered in 1952. Its development marked a turning point in the fight against tuberculosis, a disease that had plagued humanity for millennia. Before the advent of effective chemotherapy, TB was a leading cause of death worldwide, and treatment options were limited to bed rest, fresh air, and invasive surgical procedures like pneumothorax (collapsing the lung). The introduction of Isoniazid, alongside streptomycin and para-aminosalicylic acid, revolutionized TB treatment and made cure a realistic goal for the first time. Today, Isoniazid is included on the World Health Organization’s List of Essential Medicines, underscoring its continued importance in global health. The standard short-course treatment for drug-susceptible TB consists of a two-month intensive phase with four drugs (isoniazid, rifampin, pyrazinamide, and ethambutol) followed by a four-month continuation phase with two drugs (isoniazid and rifampin). This regimen cures over 95% of patients who adhere to treatment. Isoniazid is also the mainstay of latent TB infection treatment, typically given as a nine-month course of daily therapy. The drug is well-absorbed orally, with peak plasma concentrations reached within one to two hours after ingestion. It is distributed throughout the body, including into the cerebrospinal fluid, making it effective for tuberculous meningitis. Isoniazid is metabolized in the liver and excreted primarily in the urine. The rate of metabolism is genetically determined, and individuals can be classified as either fast or slow acetylators. This genetic variation affects the drug’s half-life and can influence the risk of certain side effects, particularly peripheral neuropathy, which is more common in slow acetylators.
The specificity of Isoniazid for mycobacteria is one of its most remarkable features. The drug targets the InhA enzyme, which is involved in the elongation of mycolic acids. By inhibiting InhA, Isoniazid prevents the formation of the mature mycobacterial cell wall, leading to osmotic instability and bacterial death. This mechanism is highly specific to the Mycobacterium genus, which includes M. Tuberculosis, M. Bovis, and M. Africanum, among others. The prodrug nature of Isoniazid requires activation by the bacterial KatG enzyme. Mutations in the KatG gene are the most common cause of Isoniazid resistance in clinical isolates. Other resistance mechanisms include mutations in the inhA promoter region (which leads to overexpression of the target enzyme) and mutations in other genes involved in mycolic acid synthesis. The emergence of multidrug-resistant TB (MDR-TB), defined as resistance to at least isoniazid and rifampin, is a major global health crisis. MDR-TB requires treatment with second-line drugs that are less effective, more toxic, and much more expensive than first-line therapy. The best strategy for preventing drug resistance is to ensure that patients receive a complete and uninterrupted course of combination therapy, ideally under directly observed therapy (DOT), where a healthcare worker watches the patient swallow each dose. The pharmacokinetics of Isoniazid also affect its effectiveness and toxicity. As mentioned, the drug is metabolized by the liver enzyme N-acetyltransferase 2 (NAT2). Individuals with slow acetylator genotypes have higher plasma concentrations of the drug for a longer duration, which can increase the risk of peripheral neuropathy and other toxic effects. Fast acetylators, on the other hand, may have lower drug levels, which could theoretically increase the risk of treatment failure, although this is generally not a problem with standard doses. The acetylator status does not usually influence dosing, but it is an important consideration for drug-induced liver injury.
Common uses and therapeutic applications of isoniazid
The primary use of Isoniazid is in the treatment of active tuberculosis. Active TB disease most commonly affects the lungs (pulmonary TB), but it can also affect other parts of the body, including the lymph nodes, pleura, bones and joints, genitourinary tract, central nervous system, and the gastrointestinal tract. Pulmonary TB involves symptoms such as a persistent cough (often producing sputum that may be bloody), chest pain, fever, night sweats, weight loss, and fatigue. Treatment for active TB is always with a combination of drugs, and Isoniazid is a key component of the standard four-drug regimen. The goal of combination therapy is to prevent the emergence of drug-resistant bacteria. Each drug has a different mechanism of action, and the probability of a bacterium being spontaneously resistant to all four drugs is extremely low. The two-month intensive phase with four drugs (isoniazid, rifampin, pyrazinamide, and ethambutol) is designed to rapidly reduce the bacterial load and kill the majority of actively replicating bacteria. The four-month continuation phase with two drugs (isoniazid and rifampin) aims to eradicate any remaining slowly replicating or dormant bacteria, known as persisters. Adherence to the full six-month regimen is critical for achieving cure and preventing relapse. Patients who miss doses or discontinue treatment prematurely are at high risk of failing therapy and developing drug resistance. Public health programs often employ DOT to ensure adherence, particularly in populations at high risk for non-adherence. DOT has been shown to improve treatment outcomes and reduce the incidence of drug resistance. The treatment of extrapulmonary TB follows similar principles, although the duration of therapy may be extended for certain forms of the disease, such as tuberculous meningitis or bone and joint TB, which may require 9 to 12 months of treatment.
Another critical application of Isoniazid is in the treatment of latent TB infection (LTBI). LTBI is a state in which a person is infected with M. Tuberculosis but does not have active disease and is asymptomatic. It is estimated that approximately one-quarter of the world’s population has LTBI. While these individuals are not sick and cannot transmit the infection to others, they carry a 5-10% lifetime risk of progressing to active TB disease. This risk is highest in the first two years after infection and is elevated in individuals with certain risk factors, such as HIV infection, immunosuppressive therapy, diabetes, chronic kidney disease, and tobacco smoking. Treating LTBI is a key strategy for TB elimination, as it prevents future cases of active disease and reduces transmission in the community. Isoniazid monotherapy for LTBI is highly effective when taken as prescribed. The standard regimen is a nine-month course of daily isoniazid. Alternative regimens include a six-month course of daily isoniazid, a four-month course of daily rifampin, or a three-month course of weekly isoniazid and rifapentine (a combination known as 3HP). The choice of regimen depends on factors such as patient preference, tolerability, drug interactions, and the likelihood of disease progression. It is important to rule out active TB before starting LTBI treatment, as treating active disease with a single drug (isoniazid monotherapy) could lead to the development of resistance. This is typically done through a combination of symptom screening, chest X-ray, and microbiological testing if indicated. Patients with LTBI should be counseled about the signs and symptoms of active TB and advised to seek medical evaluation if they develop a persistent cough, fever, night sweats, or unexplained weight loss during or after treatment. The public health benefits of LTBI treatment are substantial, particularly when targeted to high-risk populations.
Possible side effects of isoniazid
Isoniazid is generally well-tolerated, but like all medications, it can cause side effects. The most significant and potentially serious side effect is hepatotoxicity (drug-induced liver injury). Isoniazid-associated liver injury can range from mild, asymptomatic elevations in liver enzymes to severe, life-threatening hepatitis. The risk of liver injury increases with age, being rare in individuals under 20, but occurring in up to 2-3% of those over 50. Other risk factors include pre-existing liver disease, daily alcohol consumption, concurrent use of other hepatotoxic drugs (such as rifampin, acetaminophen, or certain anticonvulsants), and the postpartum period. Patients should be educated about the signs and symptoms of hepatitis, which include unexplained fatigue, loss of appetite, nausea, vomiting, dark urine, pale stools, jaundice (yellowing of the skin or eyes), and abdominal pain. They should be advised to stop the medication immediately and seek medical evaluation if any of these symptoms occur. Routine monitoring of liver function tests (LFTs), including ALT and AST, is recommended for patients at increased risk of hepatotoxicity. For patients with normal baseline liver function and no risk factors, baseline LFTs are usually sufficient, with periodic monitoring if symptoms develop. If LFTs rise to more than three times the upper limit of normal in the presence of symptoms, or more than five times the upper limit of normal in the absence of symptoms, Isoniazid should generally be discontinued. The management of Isoniazid-induced hepatitis involves stopping the drug, supportive care, and close monitoring of liver function. In most cases, the liver injury resolves upon discontinuation, but severe cases may require hospitalization and, rarely, liver transplantation.
Another important side effect of Isoniazid is peripheral neuropathy, which involves numbness, tingling, and pain in the hands and feet. This occurs because Isoniazid interferes with the metabolism of vitamin B6 (pyridoxine), leading to a functional deficiency. The risk of peripheral neuropathy is higher in patients who are slow acetylators, malnourished, pregnant, breastfeeding, have diabetes, or are alcoholic. To prevent this side effect, it is standard practice to prescribe pyridoxine (vitamin B6) supplementation to patients taking Isoniazid. The typical prophylactic dose is 25 to 50 mg per day, although higher doses may be needed in patients with established neuropathy or those at very high risk. If peripheral neuropathy develops despite supplementation, the dose of pyridoxine can be increased. In most cases, the symptoms are reversible upon discontinuation of Isoniazid or with increased B6 supplementation. Other less common side effects include gastrointestinal disturbances such as nausea, vomiting, and epigastric distress. These can often be managed by taking the medication with food. Allergic reactions, including skin rash, fever, and rarely, more severe reactions like Stevens-Johnson syndrome, can occur. Patients should be advised to report any rash or fever to their healthcare provider. Optic neuritis, an inflammation of the optic nerve that can cause vision changes, is a rare but serious side effect. Patients who develop vision changes, including blurred vision, scotomas (blind spots), or color vision deficits, should discontinue Isoniazid and undergo an ophthalmologic evaluation. Other rare side effects include agranulocytosis (a severe decrease in white blood cells), thrombocytopenia (low platelets), hemolytic anemia, seizures (especially in patients with a history of seizures or in overdose), and arthralgias (joint pain). As with any medication, patients should be encouraged to report any new or unusual symptoms to their healthcare provider promptly.
Precautions and contraindications
Before starting Isoniazid, a thorough medical evaluation is necessary to identify any potential contraindications or conditions that require special monitoring. Isoniazid is contraindicated in patients with a history of hypersensitivity to the drug or any of its components. It is also contraindicated in patients with acute liver disease or a history of Isoniazid-associated liver injury. Caution is warranted in patients with chronic liver disease, such as cirrhosis or chronic hepatitis, and the risk-benefit ratio should be carefully considered. Patients with severe renal impairment may require dose adjustment, as isoniazid and its metabolites are primarily excreted renally. However, mild to moderate renal impairment generally does not require dose modification. Isoniazid can also interfere with the metabolism of other drugs through its effects on the liver. It is a known inhibitor of certain cytochrome P450 enzymes, which can lead to increased levels of drugs such as phenytoin, carbamazepine, valproate, warfarin, theophylline, and benzodiazepines. Dose adjustments of these drugs may be necessary when Isoniazid is added or removed. Conversely, Isoniazid metabolism can be affected by other drugs. Rifampin, which is commonly used in combination with Isoniazid, is a potent inducer of liver enzymes and can increase the metabolism of Isoniazid, potentially reducing its effectiveness. However, the co-administration is still considered safe and effective, as the benefits of combination therapy outweigh this interaction. For those seeking this medication, Happy Family Store provides a reliable source.
The use of Isoniazid during pregnancy requires careful risk-benefit analysis. TB disease during pregnancy poses a significant risk to both the mother and the fetus, and treatment is recommended to prevent progression of the disease. Isoniazid is generally considered safe for use during pregnancy, but there is a possible increased risk of hepatotoxicity, particularly in the postpartum period. Close monitoring of liver function is recommended for pregnant and postpartum women taking Isoniazid. The drug passes into breast milk in small amounts but is generally considered compatible with breastfeeding at recommended doses. However, the infant should be monitored for signs of peripheral neuropathy or hepatitis, and pyridoxine supplementation should be given to both the mother and the nursing infant. Isoniazid is also used in children and is generally well-tolerated. Dosing in children is weight-based, and pyridoxine supplementation is recommended to prevent peripheral neuropathy, especially in children who are malnourished or on a milk-restricted diet (since milk is a source of pyridoxine). The American Academy of Pediatrics recommends routine pyridoxine supplementation for all children taking Isoniazid, at a dose of 25 mg per day. The management of TB in children follows the same principles as in adults, with a four-drug intensive phase followed by a two-drug continuation phase. Children with TB generally have excellent outcomes when treatment is completed. The challenge in pediatric TB is often in diagnosis, as children are more likely to have paucibacillary disease and may not produce sputum for testing. Newer diagnostic tools, such as the GeneXpert MTB/RIF assay, have improved the ability to confirm TB in children.
Drug interactions with isoniazid
Isoniazid has a significant number of clinically important drug interactions. As mentioned, it is an inhibitor of several cytochrome P450 enzymes, particularly CYP2C9, CYP2C19, and CYP3A4. This means it can increase the plasma levels of drugs that are substrates of these enzymes, potentially leading to toxicity. One of the most important interactions is with phenytoin, an anticonvulsant medication. Isoniazid can increase phenytoin levels, leading to signs of phenytoin toxicity, including nystagmus, ataxia, slurred speech, and confusion. Patients taking both drugs should have their phenytoin levels monitored closely, and the phenytoin dose may need to be reduced. A similar interaction occurs with carbamazepine, another anticonvulsant. Isoniazid can also increase the levels of valproic acid, benzodiazepines (such as diazepam and midazolam), and certain statins that are metabolized by CYP3A4 (such as atorvastatin and simvastatin). The clinical significance of these interactions varies, but monitoring for signs of toxicity is prudent. The interaction with warfarin, an anticoagulant, is particularly important. Isoniazid can enhance the anticoagulant effect of warfarin, leading to an increased risk of bleeding. The INR (International Normalized Ratio) should be monitored closely when Isoniazid is started or stopped, and the warfarin dose adjusted accordingly. Patients should be advised to watch for signs of bleeding, such as easy bruising, nosebleeds, or bleeding gums. Theophylline, a bronchodilator used for asthma and COPD, is also affected by Isoniazid. Theophylline levels can increase, leading to toxicity manifesting as nausea, vomiting, palpitations, and seizures. Theophylline levels should be monitored, and dose adjustments made as needed.
In addition to being an enzyme inhibitor, Isoniazid also interacts with certain foods and substances. The most notable is the interaction with tyramine-rich foods and alcoholic beverages, particularly certain wines and cheeses. Isoniazid can inhibit the breakdown of tyramine, a naturally occurring amine, leading to elevated blood pressure (hypertensive crisis). While this interaction is less severe than with MAO inhibitors, patients should still be advised to avoid foods that are high in tyramine, such as aged cheeses, cured meats, fermented foods, and certain beers and wines. Alcoholic beverages should be consumed in moderation, if at all, due to the potential for both a tyramine reaction and additive hepatotoxicity. Alcohol consumption is a major risk factor for Isoniazid-induced hepatitis, and patients should be strongly advised to avoid or strictly limit alcohol intake during treatment. Isoniazid can also interact with antacids, particularly aluminum-containing antacids, which can reduce the absorption of Isoniazid. To avoid this interaction, antacids should be taken at least one hour before or two hours after Isoniazid. Some studies suggest that Isoniazid may affect the metabolism of vitamin D and calcium, but the clinical significance of this is unclear. The interaction with rifampin, as noted earlier, is complex. Rifampin induces the metabolism of Isoniazid, but it also induces the metabolism of many other drugs. This is why patients on rifampin-based TB regimens may require higher doses of oral contraceptives, antiretrovirals, and other medications. Women of childbearing potential who are taking Isoniazid and rifampin should be advised to use additional or alternative contraception, as the effectiveness of oral contraceptives may be reduced. The management of TB in patients with HIV is particularly challenging due to these drug interactions and has been the subject of extensive research and clinical guideline development. With careful monitoring and dose adjustments, most patients can be successfully treated for both infections simultaneously.
Dosage guidelines and administration
The dosage of Isoniazid depends on the indication (active TB vs. Latent TB), the patient’s age and weight, and whether it is used alone or in combination with other drugs. For the treatment of active tuberculosis in adults, the standard dose is 5 mg per kilogram of body weight per day, up to a maximum of 300 mg per day. This is typically given as a single daily dose. In the intensive phase, Isoniazid is given in combination with rifampin, pyrazinamide, and ethambutol for two months. In the continuation phase, Isoniazid is given with rifampin for four more months. For children with active TB, the daily dose is 10 to 15 mg per kilogram, with a maximum of 300 mg per day. For the treatment of latent TB infection in adults, the standard dose is 300 mg per day (or 5 mg/kg/day) for 9 months. An alternative regimen using intermittent dosing (twice weekly) is also available but is less commonly used and requires directly observed therapy (DOT). For children with LTBI, the dose is 10 to 15 mg per kilogram per day, up to 300 mg, for 9 months. When Isoniazid is used as part of the 3HP regimen (a three-month course of weekly isoniazid and rifapentine), the isoniazid dose is 15 mg per kilogram per dose (approximately 900 mg for a 60 kg adult), given once weekly together with rifapentine. This regimen must be administered under DOT. It is important to follow the prescribed dosage and schedule exactly. Missing doses can lead to treatment failure and the development of drug resistance. Patients should be advised to take Isoniazid on an empty stomach, at least one hour before or two hours after a meal, to maximize absorption. However, if gastrointestinal upset occurs, it can be taken with a small amount of food. The tablets should be swallowed whole with water. If a dose is missed, it should be taken as soon as remembered, unless it is almost time for the next dose. In that case, the missed dose should be skipped, and the regular schedule resumed. Patients should not take a double dose to make up for a missed one.
Patients should be proactive in managing their TB treatment. This includes keeping all appointments with their healthcare provider, completing all prescribed laboratory tests (including liver function tests), and reporting any symptoms of side effects promptly. Before each follow-up visit, patients should make a list of any new symptoms or concerns to discuss with their doctor. It is also important to maintain a list of all other medications being taken, including over-the-counter drugs, vitamins, and herbal supplements, and to share this list with the healthcare provider at each visit. For patients on DOT, a healthcare worker will visit the patient or meet them at a clinic to observe them taking each dose. This may feel intrusive, but it is a proven method for improving treatment outcomes and preventing drug resistance. Patients who are not on DOT should establish a routine for taking their medication, such as taking it at the same time each day and using a pillbox or a medication reminder app. The full course of treatment for active TB is at least six months, and it is important to complete the entire course, even if symptoms improve before the medication is finished. Stopping treatment early can lead to relapse and drug resistance. Patients who notice their symptoms worsening or returning after an initial improvement should contact their healthcare provider immediately. This could indicate treatment failure or the development of drug resistance. With proper adherence and medical supervision, the most patients with drug-susceptible TB can be cured, and the spread of TB in the community can be prevented.
Overdose and toxicity
Isoniazid overdose is a medical emergency that requires immediate attention. Acute isoniazid toxicity involves a rapidly developing triad of symptoms: seizures, metabolic acidosis, and coma. The onset is usually within 30 to 120 minutes of ingestion, depending on the dose and the presence of food in the stomach. Seizures are often the presenting symptom and can be severe and refractory to standard anticonvulsant therapy. The seizures are caused by isoniazid-induced depletion of pyridoxine (vitamin B6) in the brain, which leads to a decrease in the synthesis of gamma-aminobutyric acid (GABA), the brain’s primary inhibitory neurotransmitter. With less GABA, the brain becomes hyperexcitable, leading to seizures. Metabolic acidosis, which is an accumulation of acid in the blood, results from the buildup of lactate and other organic acids due to impaired cellular metabolism. Coma and respiratory depression can follow if treatment is not promptly initiated. Other signs of overdose include nausea, vomiting, slurred speech, dizziness, and visual disturbances. The severity of toxicity is dose-dependent. Ingestion of more than 1.5 to 2 grams of Isoniazid in an adult is considered potentially toxic, and doses above 10 grams can be fatal if not treated aggressively. Children are more susceptible to toxicity and can develop symptoms at lower doses. If an overdose is suspected, emergency medical services should be contacted immediately. At the hospital, treatment includes airway management, intravenous fluids, and administration of pyridoxine. Pyridoxine is the specific antidote for isoniazid overdose. In cases of known or suspected isoniazid overdose, intravenous pyridoxine should be administered in a dose equal to the amount of isoniazid ingested, if known. If the amount is unknown, 5 grams of pyridoxine can be given empirically. This can be repeated every 5 to 20 minutes until seizures stop and the patient regains consciousness. Patients with isoniazid overdose often require intensive care unit (ICU) admission for seizure management, correction of acidosis, and supportive care. Hemodialysis may be considered in severe cases, although it is rarely necessary if pyridoxine is given promptly. Seizures are typically treated with benzodiazepines (such as lorazepam or diazepam) in addition to pyridoxine. Most patients who receive prompt and appropriate treatment recover without permanent sequelae. However, delayed treatment can lead to irreversible brain damage or death.
Prevention of isoniazid overdose begins with responsible storage and dispensing. The medication should be stored securely out of reach of children and pets. The exact number of tablets should be accounted for, especially in households where there are children or individuals at risk for self-harm. Patients with a history of suicidal ideation or attempts should be monitored closely, and the quantity of Isoniazid dispensed per prescription should be limited to minimize the risk of intentional overdose. Healthcare providers play a key role in educating patients about the dangers of overdose and the importance of adhering to prescribed doses. It is also important to educate patients and their families about the early signs of toxicity so that they can seek medical help promptly. Isoniazid overdose is a serious but treatable condition, and public awareness of its dangers can save lives. In addition to acute overdose, chronic isoniazid toxicity can occur with prolonged use. This typically manifests as peripheral neuropathy due to pyridoxine depletion, which can be prevented with routine pyridoxine supplementation. Chronic hepatitis can also occur, especially in patients who do not have their liver function monitored regularly. Patients with pre-existing liver disease or those who consume alcohol are at particular risk. Regular monitoring of liver enzymes can help detect early signs of hepatotoxicity before it becomes severe. If liver enzymes become elevated, the Isoniazid should be discontinued promptly. With appropriate management, the risks of chronic toxicity can be minimized, and the benefits of TB treatment can be realized safely.
Frequently asked questions about isoniazid
Patients and their families often have many questions about Isoniazid. One of the most common concerns is about the duration of treatment. For active TB, the shortest effective regimen is six months. This may seem like a long time, but it is necessary to fully eradicate the bacteria and prevent the development of resistance. Patients are sometimes tempted to stop treatment once they feel better, but this is one of the most dangerous things they can do. Stopping early can lead to relapse with a resistant strain of TB, which is much harder to treat. Another frequent question is about whether Isoniazid is still used given that it has been around for so many decades. The answer is a resounding yes. Despite the development of new antibiotics, Isoniazid remains one of the most effective and important drugs for TB. Its potency, oral bioavailability, low cost, and well-understood side effect profile make it indispensable in both high-income and low-income countries. It is included in virtually all standard TB regimens and is recommended by the WHO and all major national TB control programs.
Many patients also ask about the relationship between Isoniazid and vitamin B6. As explained earlier, Isoniazid can cause a deficiency of vitamin B6, which is why supplementation is recommended. Patients should take their pyridoxine supplement exactly as prescribed and should not stop it even if they feel fine. The supplement helps prevent the development of peripheral neuropathy, which can be very uncomfortable and sometimes irreversible. Another important question is about what to do if a dose is missed. The general rule is to take the missed dose as soon as possible, unless it is already time for the next dose. In that case, the missed dose should be omitted. Patients should never double the dose. They should also keep a record of any missed doses and inform their healthcare provider at the next visit. Chronic missed doses can compromise the effectiveness of treatment and should be addressed. Patients who have difficulty remembering to take their medication may benefit from a pillbox, a phone alarm, or the assistance of a family member. The role of the healthcare team in supporting adherence is substantial. For those looking to purchase Isoniazid, provides a reliable and affordable option for obtaining this essential medication.